Hepatitis Monthly

Published by: Kowsar

Risk of HBV Reactivation in Patients Infected with HBV/HCV Treated with DAA

Malgorzata Pawlowska 1 , * and Krzysztof Domagalski 2
Authors Information
1 Department of Paediatric Infectious Diseases and Haepatology, Faculty of Medicine, Nicolaus Copernicus University, Bydgoszcz, Poland
2 Centre for Modern Interdisciplinary Technologies, Nicolaus Copernicus University, Torun, Poland
Article information
  • Hepatitis Monthly: August 2017, 17 (8); e12317
  • Published Online: August 4, 2017
  • Article Type: Review Article
  • Received: April 30, 2017
  • Revised: May 30, 2017
  • Accepted: August 28, 2017
  • DOI: 10.5812/hepatmon.12317

To Cite: Pawlowska M, Domagalski K. Risk of HBV Reactivation in Patients Infected with HBV/HCV Treated with DAA, Hepat Mon. 2017 ; 17(8):e12317. doi: 10.5812/hepatmon.12317.

Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl)-57[DOI][PubMed]
  • 2. Polaris Observatory H. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017; 2(3): 161-76[DOI][PubMed]
  • 3. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008; 23(4): 512-20[DOI][PubMed]
  • 4. Crockett SD, Keeffe EB. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob. 2005; 4: 13[DOI][PubMed]
  • 5. Yu G, Chi X, Wu R, Wang X, Gao X, Kong F, et al. Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population. PLoS One. 2015; 10(9)[DOI][PubMed]
  • 6. Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology. 2013; 58(2): 538-45[DOI][PubMed]
  • 7. Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology. 2010; 51(3): 759-66[DOI][PubMed]
  • 8. Wang C, Ji D, Chen J, Shao Q, Li B, Liu J, et al. Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents. Clin Gastroenterol Hepatol. 2017; 15(1): 132-6[DOI][PubMed]
  • 9. Liu JY, Sheng YJ, Hu HD, Zhong Q, Wang J, Tong SW, et al. The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Virol J. 2012; 9: 186[DOI][PubMed]
  • 10. Ende AR, Kim NH, Yeh MM, Harper J, Landis CS. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015; 9: 164[DOI][PubMed]
  • 11. Colson P, Borentain P, Coso D, Motte A, Aurran-Schleinitz T, Charbonnier A, et al. Hepatitis B virus reactivation in HBsAg-negative patients is associated with emergence of viral strains with mutated HBsAg and reverse transcriptase. Virology. 2015; 484: 354-63[DOI][PubMed]
  • 12. Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study. Clin Infect Dis. 2015; 61(5): 719-29[DOI][PubMed]
  • 13. Liu CJ, Chen PJ, Chen DS, Kao JH. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int. 2013; 7(2): 316-26[DOI][PubMed]
  • 14. Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, et al. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology. 2013; 57(6): 2135-42[DOI][PubMed]
  • 15. Vigano M, Aghemo A, Iavarone M, Rumi MG, Agnelli F, Lampertico P, et al. The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. Antivir Ther. 2009; 14(6): 789-96[DOI][PubMed]
  • 16. Wahle RC, Perez RM, Pereira PF, Oliveira EM, Emori CT, Uehara SN, et al. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection. Braz J Infect Dis. 2015; 19(5): 533-7[DOI][PubMed]
  • 17. Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology. 2017; 66(1): 13-26[DOI][PubMed]
  • 18. Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, et al. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin Infect Dis. 2015; 61(8): 1304-6[DOI][PubMed]
  • 19. De Monte A, Courjon J, Anty R, Cua E, Naqvi A, Mondain V, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016; 78: 27-30[DOI][PubMed]
  • 20. Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res. 2016; 46(5): 489-91[DOI][PubMed]
  • 21. Ou P, Fang Z, Chen J. Hepatitis B reactivation in a chronic hepatitis C patient treated with ledipasvir and sofosbuvir: A case report. Clin Res Hepatol Gastroenterol. 2017; 41(2)-8[DOI][PubMed]
  • 22. Garcia MP, Hernandez IL, Cuenca FF, Rios Villegas MJ. Acute B hepatitis after hepatitis C virus therapy with direct acting antivirals in a co-infected patient with HIV. J Liver. 2016; 5(3)[DOI]
  • 23. Yeh ML, Huang CF, Hsieh MH, Ko YM, Chen KY, Liu TW, et al. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. J Gastroenterol Hepatol. 2017; [DOI][PubMed]
  • 24. Sulkowski MS, Chuang WL, Kao JH, Yang JC, Gao B, Brainard DM, et al. No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. Clin Infect Dis. 2016; 63(9): 1202-4[DOI][PubMed]
  • 25. Gane EJ, Hyland RH, An D, Svarovskaia ES, Brainard D, McHutchison JG. Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV. Antivir Ther. 2016; 21(7): 605-9[DOI][PubMed]
  • 26. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C.
  • 27. AASLD/ISDA . HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C.
  • 28. European Medicines Agency (EMA) . PRAC warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C [news release].
  • 29. European Medicines Agency (EMA) . Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments